Graduated from Cardiff University in 2017. During his third year, he undertook a placement at the University of Maryland, Baltimore, working with Prof. Steven Fletcher where he developed inhibitors of the Mcl-1 oncoprotein and a method for the synthesis of substituted 3-hydroxybenzisoxazoles via the Mitsunobu reaction. In his final year, he worked in the lab of Prof. Rudolf Allemann on developing a semi-synthetic route to the antimalarial drug, (+)-artemisinin, facilitated by the enzyme amorpha-4,11-diene synthase (ADS). He joined the Bristol Chemical Synthesis CDT in 2017 and then the Davis group. His project involves developing receptors for binding carbohydrates in aqueous media.